Jeffrey T. Blue

735 total citations
18 papers, 549 citations indexed

About

Jeffrey T. Blue is a scholar working on Molecular Biology, Epidemiology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jeffrey T. Blue has authored 18 papers receiving a total of 549 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Epidemiology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jeffrey T. Blue's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Protein purification and stability (8 papers) and Pneumonia and Respiratory Infections (5 papers). Jeffrey T. Blue is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Protein purification and stability (8 papers) and Pneumonia and Respiratory Infections (5 papers). Jeffrey T. Blue collaborates with scholars based in United States, Switzerland and Germany. Jeffrey T. Blue's co-authors include Brian K. Meyer, Danny K. Chou, Thomas M. Spitznagel, Satish Kumar Singh, Michel Awwad, Linda O. Narhi, Hanns‐Christian Mahler, Nataliya Afonina, Karoline Bechtold-Peters and Mary Cromwell and has published in prestigious journals such as The Journal of Immunology, Pharmaceutical Research and Journal of Pharmaceutical Sciences.

In The Last Decade

Jeffrey T. Blue

18 papers receiving 527 citations

Peers

Countries citing papers authored by Jeffrey T. Blue

Since Specialization

Citations

This map shows the geographic impact of Jeffrey T. Blue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey T. Blue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey T. Blue more than expected).

Fields of papers citing papers by Jeffrey T. Blue

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey T. Blue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey T. Blue. The network helps show where Jeffrey T. Blue may publish in the future.

Co-authorship network of co-authors of Jeffrey T. Blue

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey T. Blue. A scholar is included among the top collaborators of Jeffrey T. Blue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey T. Blue. Jeffrey T. Blue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Impact of aluminum adjuvants on the stability of pneumococcal polysaccharide-protein conjugate vaccines 2023 ·Vaccine ·William J. Smith, Rachel Thompson, (unknown), Yuhua Zhang, (unknown), Julie M. Skinner, Jeffrey T. Blue, Michael A. Winters	4
2	Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines 2022 ·Vaccines ·Beth-Ann Coller, William Lapps, (unknown), Samantha Bruno, M.J. Eichberg, (unknown), Kenneth Liu, Rosybel Drury, (unknown), (unknown), Thomas Armstrong, Jeffrey T. Blue, Lynne A. Isopi, Melissa E. Hughes, Susan M. VanRheenen, Jonathan Deutsch, Joan G. Tell, Sheri Dubey	6
3	Analytical technology development to monitor the stability of Polysaccharide-Protein conjugate vaccines 2022 ·Vaccine ·William J. Smith, Patrick L. Ahl, Bei Wang, Melissa Hamm, Richard R. Rustandi, Michael A. Winters, Jeffrey T. Blue	4
4	Evaluation of Microwave Vacuum Drying as an Alternative to Freeze-Drying of Biologics and Vaccines: the Power of Simple Modeling to Identify a Mechanism for Faster Drying Times Achieved with Microwave 2021 ·AAPS PharmSciTech ·Akhilesh Bhambhani, (unknown), Daniel Roth, Elizabeth Sullivan, (unknown), Robert Evans, Jeffrey T. Blue	23
5	Examination of the effect of agitation on the potency of the Ebola Zaire vaccine rVSVΔG-ZEBOV-GP 2020 ·Vaccine ·(unknown), (unknown), Lynne A. Isopi, Jeffrey T. Blue	9
6	Enabling Lyophilized Pneumococcal Conjugate Vaccines Through Formulation Design and Excipient Selection Suitable for A Multivalent Adjuvanted Vaccine 2020 ·Journal of Pharmaceutical Sciences ·(unknown), Ramesh Chintala, Denise K. Nawrocki, Jeffrey T. Blue, Akhilesh Bhambhani	6
7	Quantitative Analysis of Vaccine Antigen Adsorption to Aluminum Adjuvant Using an Automated High-Throughput Method 2018 ·PDA Journal of Pharmaceutical Science and Technology ·Patrick L. Ahl, (unknown), Ramesh Chintala, (unknown), William J. Smith, (unknown), Jeffrey T. Blue	3
8	High Throughput Differential Scanning Fluorimetry (DSF) Formulation Screening with Complementary Dyes to Assess Protein Unfolding and Aggregation in Presence of Surfactants 2018 ·Pharmaceutical Research ·Sean M. McClure, Patrick L. Ahl, Jeffrey T. Blue	31
9	Characterization of Propylene Glycol-Mitigated Freeze/Thaw Agglomeration of a Frozen Liquid nOMV Vaccine Formulation by Static Light Scattering and Micro-Flow Imaging. 2018 ·PubMed ·(unknown), (unknown), Jeffrey T. Blue	2
10	Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic 2017 ·Vaccine ·Beth-Ann Coller, Jeffrey T. Blue, Rituparna Das, Sheri Dubey, L. Finelli, (unknown), F.A. Helmond, Rebecca J. Grant-Klein, Kenneth Liu, Jakub K. Simon, Sean P. Troth, Susan M. VanRheenen, Julie A. Waterbury, (unknown), Jayanthi Wolf, D. Gray Heppner, Tracy Kemp, Richard Nichols, Thomas P. Monath	35
11	Accelerating Vaccine Formulation Development Using Design of Experiment Stability Studies 2016 ·Journal of Pharmaceutical Sciences ·Patrick L. Ahl, (unknown), (unknown), (unknown), Lan Zhang, (unknown), (unknown), William J. Smith, Craig T. Przysiecki, (unknown), Jeffrey T. Blue	6
12	Development, manufacturing, and supply of MSD’s Ebola vaccine 2016 ·Jeffrey T. Blue	3
13	Detecting and preventing reversion to toxicity for a formaldehyde-treated C. difficile toxin B mutant 2014 ·Vaccine ·(unknown), Su Wang, Richard R. Rustandi, Feng Wang, (unknown), (unknown), (unknown), Susan Secore, Geethanjali Dornadula, (unknown), Jon H. Heinrichs, Henryk Mach, Jeffrey T. Blue, David S. Thiriot	12
14	High Throughput Formulation Screening for Global Aggregation Behaviors of Three Monoclonal Antibodies 2011 ·Journal of Pharmaceutical Sciences ·(unknown), Henryk Mach, Jeffrey T. Blue	38
15	Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model 2011 ·Vaccine ·Julie M. Skinner, (unknown), Jayme Cannon, Jeffrey T. Blue, Michael A. Winters, John E. MacNair, Narahari S. Pujar, (unknown), Yuhua Zhang, Joseph M. Antonello, John W. Shiver, Michael J. Caulfield, Jon H. Heinrichs	67
16	Preclinical evaluation of a 15-valent pneumococcal polysaccharide-protein conjugate vaccine in infant rhesus monkeys (52.20) 2010 ·The Journal of Immunology ·Julie M. Skinner, (unknown), Michael A. Winters, John E. MacNair, (unknown), Hari Pujar, Jeffrey T. Blue, Joseph M. Antonello, Jon H. Heinrichs, Michael J. Caulfield	2
17	The Use of Flow Cytometry for the Detection of Subvisible Particles in Therapeutic Protein Formulations 2010 ·Journal of Pharmaceutical Sciences ·Henryk Mach, Akhilesh Bhambhani, Brian K. Meyer, (unknown), (unknown), Jeffrey T. Blue, Robert K. Evans	35
18	An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein Therapeutics 2010 ·Journal of Pharmaceutical Sciences ·Satish Kumar Singh, Nataliya Afonina, Michel Awwad, Karoline Bechtold-Peters, Jeffrey T. Blue, Danny K. Chou, Mary Cromwell, (unknown), Hanns‐Christian Mahler, Brian K. Meyer, Linda O. Narhi, (unknown), Thomas M. Spitznagel	263

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact